Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
2.

Oncology pharmacists in health care delivery: vital members of the cancer care team.

Holle LM, Boehnke Michaud L.

J Oncol Pract. 2014 May;10(3):e142-5. doi: 10.1200/JOP.2013.001257. Epub 2014 Mar 11. No abstract available.

PMID:
24618076
3.

Antiemesis.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):456-85. No abstract available.

PMID:
22491046
4.

Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.

Michaud LB.

Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 3):S20-30; quiz S31-3. doi: 10.2146/ajhp100078.

PMID:
20332495
5.

The epothilones: how pharmacology relates to clinical utility.

Michaud LB.

Ann Pharmacother. 2009 Jul;43(7):1294-309. doi: 10.1345/aph.1M005. Epub 2009 Jul 7. Review.

PMID:
19584389
6.

Myeloid growth factors.

Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Jan;7(1):64-83. No abstract available.

PMID:
19176207
7.

The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.

Boehnke Michaud L.

J Oncol Pharm Pract. 2009 Jun;15(2):95-106. doi: 10.1177/1078155208100095. Epub 2009 Jan 26. Review.

PMID:
19171553
8.

Treatment-experienced breast cancer.

Michaud LB.

Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S4-9. doi: 10.2146/ajhp080088.

PMID:
18463331
9.

Myeloid growth factors. Clinical practice guidelines in oncology.

Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Feb;5(2):188-202. No abstract available.

PMID:
17335688
10.

Dietary supplements in patients with cancer: risks and key concepts, part 2.

Michaud LB, Karpinski JP, Jones KL, Espirito J.

Am J Health Syst Pharm. 2007 Mar 1;64(5):467-80. Review.

PMID:
17322159
11.

Dietary supplements in patients with cancer: risks and key concepts, part 1.

Michaud LB, Karpinski JP, Jones KL, Espirito J.

Am J Health Syst Pharm. 2007 Feb 15;64(4):369-81. Review.

PMID:
17299176
12.

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ.

J Clin Oncol. 2006 Sep 1;24(25):4107-15. Epub 2006 Aug 14. Erratum in: J Clin Oncol. 2008 May 10;26(14): 2421.

PMID:
16908934
13.

Cancer-treatment-induced bone loss, part 2.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 15;63(6):534-46. Review.

PMID:
16522890
14.

Cancer-treatment-induced bone loss, part 1.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 1;63(5):419-30. Review.

PMID:
16484516

Supplemental Content

Loading ...
Support Center